Charlotte Robinson

DocwireNews

Akebia Therapeutics announced two major updates regarding the commercial launch of its drug Vafseo (vadadustat) for anemia related to chronic kidney disease.Firstly, the drug maker has terminated its license agreement with CSL Vifor for the drug and has regained full rights to sell Vafseo directly to dialysis organizations in the United States. &ldquo;Having now executed this agreement with CSL Vifor, we can accelerate contracting discussions and expect to have contracts in place with dialysis providers treating the vast majority of eligible Vafseo patients before January 2025,&rdquo; said John P. Butler, chief executive officer of Akebia.Secondly, Akebia announced wholesale acquisition cost (WAC) pricing for Vafseo, which has been set at $1278 for a 30-day supply at the minimum starting dose, or approximately $15,500 per year. Vafseo was approved in March for use in patients on dialysis only. However, the WAC pricing accounts for a potential label expansion into nondialysis patients. All dialysis business will be contracted, and off-invoice discounts and volume-tier discounts will be available.Akebia submitted a Transitional Drug Add-On Payment Adjustment (TDAPA) application for Vafseo in June. The company expects to have Healthcare Common Procedure Coding System codes assigned in October 2024 and full TDAPA designation by January 1, 2025.

Jayme Locke, MD, MPH

Joel M. Topf, MD, FACP

The Promise of Xenotransplantation

NKF Spring Clinical Meetings 2025

Leah Lawrence

Real-World Data Backs Invasive DFS as Surrogate Endpoint for OS in EBC

HR Breast Cancer

Sacituzimab Govitecan Showed Modest Activity for CNS Metastases

Triple-Negative Breast Cancer

Latest News

Akebia Regains Rights to Vafseo, Sets New Price

Anemia and Kidney Disease

Akebia Therapeutics has ended its license agreement with CSL Vifor for Vafseo (vadadustat) and announced wholesale acquisition cost pricing for the CKD-related anemia drug.

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe